NCT03789682

Brief Summary

This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
151

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2018

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

December 27, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 28, 2018

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

April 16, 2025

Status Verified

April 1, 2025

Enrollment Period

5 years

First QC Date

December 27, 2018

Last Update Submit

April 13, 2025

Conditions

Bladder Cancer

Outcome Measures

Primary Outcomes (1)

  • Recurrence free survival

    Time to recurrence or metastasis

    2018.1.1-2023.12.31

Secondary Outcomes (3)

  • Overall survival

    2018.1.1-2028.1.1

  • Benefit from neoadjuvant chemotherapy

    2018.1.1-2028.1.1

  • Benefit from adjuvant chemotherapy

    2018.1.1-2028.1.1

Study Arms (1)

FUSCC cystectomy cohort

patients underwent cystectomy in Fudan University Shanghai Cancer Center

Drug: Adjuvant chemotherapy

Interventions

Adjuvant chemotherapyDRUG

adjuvant chemotherapy using Gemcitabine plus Cisplatin

FUSCC cystectomy cohort

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with non-metastatic muscle invasive bladder cancer underwent cystectomy in Fudan University Shanghai Cancer Center is included

You may qualify if:

  • patients with non-metastatic muscle invasive bladder cancer
  • pathology confirmed urothelial carcinoma
  • underwent cystectomy and pelvic lymph node dissection

You may not qualify if:

  • not enough tissue for immunohistochemistry
  • patients with a second neoplasm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Interventions

Chemotherapy, Adjuvant

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeuticsDrug Therapy

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department of Urology

Study Record Dates

First Submitted

December 27, 2018

First Posted

December 28, 2018

Study Start

January 1, 2018

Primary Completion

January 1, 2023

Study Completion

January 1, 2025

Last Updated

April 16, 2025

Record last verified: 2025-04

Locations

CN(1)